With over 16,000 attendees from more than 110 countries, the ACR Annual Meeting remains the number one congress for rheumatology worldwide. Travelers from around the world know generally to expect mild weather if the meeting is in California and colder weather if further north. The 2019 ACR congress took place in the Deep South at Atlanta, Georgia where the delegates were taken by surprise by a few days of icy artic weather. However, this in no way detracted from an excellent meeting. If you want to look back on the conference or find out what you missed, this peer-reviewed report contains several highlights presented at the meeting.
The expanding data on JAK inhibitors in rheumatoid arthritis keeps showing promise, with the concept of monotherapy gaining more and more traction. Therapeutic advances have also been made in vasculitis and SLE, disorders not usually taking centre stage. As clinicians recognise the importance of listening to the patient’s voice, this meeting showed an increased focus on patient-reported outcomes including pain and fatigue.
Hopefully, many of the things we have highlighted including therapy developments and how we will evaluate patients in the coming years will be foreshadowed in this publication. We hope you enjoy the report!
Medicom Medical Publishers
Posted on
Previous Article
« Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib Next Article
Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis »
« Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib Next Article
Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis »
Table of Contents: ACR 2019
Featured articles
Late-Breaking Abstracts
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Calcium pyrophosphate deposition disease: an independent risk factor for cardiovascular complications
Proteome abnormalities improve prediction of RA development
RA patients in remission benefit from continued therapy with conventional DMARDs
Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis
Corticosteroid therapy in GCA: higher platelets – lower relapse rate
Spotlight on Rheumatoid Arthritis
Filgotinib promising in RA patients naïve to methotrexate
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
Biologics show similar activity in patients with elderly-onset RA
Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration
Treatment decisions should not be guided by ultrasound findings
Cancer treatment with checkpoint inhibitors in RA patients?
What is Hot in Systemic Lupus Erythematosus
Anifrolumab succeeds in second phase 3 trial in SLE
Depression closely related to fatigue in SLE patients
Spondyloarthritis – The Beat Goes On
Psoriasis onset determines sequence of symptoms
Higher psychiatric comorbidity in women with PsA
JAK1 inhibition shows remarkable efficacy in AS
CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients
Osteoarthritis – State-of-the-Art
Hand OA: low-dose corticosteroids improve symptoms
Opioids: no quality of life benefits for OA patients
Walking speed is a predictor of mortality in patients with knee OA
Reproductive Issues in Rheumatic Disease
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Prevention of congenital heart block may be possible with hydroxychloroquine
TNFi for RA during pregnancy – to stop or not to stop?
Vasculitis – Novel Treatment Modalities
Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis
Prolonged remission after stop of tocilizumab for patients with giant cell arteritis
Best of the Posters
Antifibrotic therapy slows disease progression independent of corticosteroid use
Fibromyalgia patients often experienced abuse in childhood
Related Articles
March 4, 2022
Plasma exchange works for ANCA-associated vasculitis
October 24, 2018
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com